Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy

Taheri, Mojtaba; Tehrani, Hossein Abdul; Daliri, Fatemeh; Alibolandi, Mona; Soleimani, Masoud; Shoari, Alireza; Arefian, Ehsan; Ramezani, Mohammad

doi:10.1016/j.cytogfr.2023.09.005

Cited by 3 publications

(1 citation statement)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…140,142,143 Several studies have reported that genetically engineered MSCs expressing cytokines can overcome the immunosuppressive condition in TME. To date, MSCs have been used as a vehicle for the selective delivery of a wide variety of cytokines, including IL-2, 144 IL-12, 31 IL-18, 145,146 IFN-α, 147 and Interferon beta (IFN-β) 142 to various cancer models.…”

Section: The Potential Of Msc As a Therapeutic Delivery Tool In Cance...mentioning

confidence: 99%

Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle

Taheri,

Tehrani,

Dehghani

et al. 2024

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

Targeting actionable mutations in oncogene‐driven cancers and the evolution of immuno‐oncology are the two prominent revolutions that have influenced cancer treatment paradigms and caused the emergence of precision oncology. However, intertumoral and intratumoral heterogeneity are the main challenges in both fields of precision cancer treatment. In other words, finding a universal marker or pathway in patients suffering from a particular type of cancer is challenging. Therefore, targeting a single hallmark or pathway with a single targeted therapeutic will not be efficient for fighting against tumor heterogeneity. Mesenchymal stem cells (MSCs) possess favorable characteristics for cellular therapy, including their hypoimmune nature, inherent tumor‐tropism property, straightforward isolation, and multilineage differentiation potential. MSCs can be loaded with various chemotherapeutics and oncolytic viruses. The combination of these intrinsic features with the possibility of genetic manipulation makes them a versatile tumor delivery vehicle that can be used for in vivo selective tumor delivery of various chemotherapeutic and biological therapeutics. MSCs can be used as biofactory for the local production of chemical or biological anticancer agents at the tumor site. MSC‐mediated immunotherapy could facilitate the sustained release of immunotherapeutic agents specifically at the tumor site, and allow for the achievement of therapeutic concentrations without the need for repetitive systemic administration of high therapeutic doses. Despite the enthusiasm evoked by preclinical studies that used MSC in various cancer therapy approaches, the translation of MSCs into clinical applications has faced serious challenges. This manuscript, with a critical viewpoint, reviewed the preclinical and clinical studies that have evaluated MSCs as a selective tumor delivery tool in various cancer therapy approaches, including gene therapy, immunotherapy, and chemotherapy. Then, the novel nanotechnology and bioengineering approaches that can improve the potency of MSC for tumor targeting and overcoming challenges related to their low localization at the tumor sites are discussed.

show abstract

Section: The Potential Of Msc As a Therapeutic Delivery Tool In Cance...mentioning

confidence: 99%

Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle

Taheri,

Tehrani,

Dehghani

et al. 2024

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies

Cheng,

Cui,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Greppi,

De Franco,

Obino

et al. 2024

Immunology Letters

View full text Add to dashboard Cite

Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy

Cited by 3 publications

References 159 publications

Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle

Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle

Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies

NK cell receptors in anti-tumor and healthy tissue protection: Mechanisms and therapeutic advances

Contact Info

Product

Resources

About